| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
N6-Benzyladenosine targets adenosine receptors, particularly the A1 adenosine receptor subtype. Adenosine receptors are G protein-coupled receptors that mediate the effects of adenosine in various physiological processes including neurotransmission, inflammation, and cardiovascular function. As an A1 receptor agonist, N6-Benzyladenosine activates A1 receptor-mediated signaling pathways, which can inhibit adenylyl cyclase and modulate neuronal excitability. The compound also exhibits cytokinin activity.
|
|---|---|
| ln Vitro |
The clonogenic activity and proliferation of several tumor cells are inhibited by N6-benzyladenosine [2]. Actin cytoskeleton breakdown and morphological alterations in T24 cells are caused by N6-benzyladenosine [2]. Potently inducing apoptosis, N6-benzyladenosine (10 μM; 24 h) is a member of the apoptotic system with differential activation of caspase-3 and caspase-9 [3]. Dose-dependent chromatin condensation, apoptotic body formation, and DNA breakage into nucleosomal fragments are all induced by N6-benzyladenosine (0-100 μM; 24 h) [3]. N6-benzyladenosine functions as a more effective and selective anti-Toxoplasma gondii agent than human adenosine kinase, with a higher binding affinity of 179.8 μM to Toxoplasma gondii adenosine kinase [4]. When applied to Toxoplasma gondii strains defective in adenosine kinase (TgAKS3), N6-benzyladenosine (0-50 μM) exhibits mild inhibitory effects [4]. Compound 2 (N6-benzyladenosine) (0.3–20 μM) inhibits farnesyl pyrophosphate synthase (FPPS) and tampers with the mevalonate pathway to provide anti-glioma effects [5].
In vitro, N6-Benzyladenosine is an adenosine receptor agonist with cytokinin activity. It is a selective A1 adenosine receptor agonist. The compound induces G0/G1 cell cycle arrest and apoptosis. Its ability to activate adenosine receptors and induce cell cycle arrest makes it valuable for studying adenosine signaling, cell proliferation, and apoptosis in various cell types. |
| ln Vivo |
In vivo, N6-Benzyladenosine is used in research to study adenosine receptor signaling and its physiological roles. As an adenosine receptor agonist, it has potential applications in studying neurological, cardiovascular, and inflammatory processes. However, specific in vivo efficacy data for N6-Benzyladenosine have not been detailed in the available literature.
|
| Enzyme Assay |
For in vitro receptor binding assays, cells expressing adenosine receptors or membrane preparations are incubated with radiolabeled ligands at various concentrations of N6-Benzyladenosine (0.1-1000 nM). Binding affinity (Ki) is determined using radioligand binding assays. For functional assays, receptor activation is measured by assessing cAMP accumulation or other downstream signaling events.
|
| Cell Assay |
Apoptosis analysis[3]
Cell Types: HL-60 Tested Concentrations: 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptosis by increasing caspase-3 (DEVDase) and caspase-9 (LEHDase) activity, indicating apoptotic system With significant caspase-3/9 activation. Apoptosis analysis [5] Cell Types: U87MG human glioma cell line. Tested Concentrations: 0.3, 0.6, 1.2, 2.5, 5, 10, 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited glioma growth by interfering with the mevalonate pathway and inhibiting FPPS. For cell-based assays, cells expressing adenosine receptors are treated with N6-Benzyladenosine at concentrations ranging from 0.1-100 µM. Receptor activation is assessed by measuring cAMP levels or other downstream signaling events. Cell cycle analysis is performed by flow cytometry after propidium iodide staining to assess G0/G1 arrest. Apoptosis is assessed by measuring caspase activity or by Annexin V staining. |
| Animal Protocol |
For in vivo studies, animal models of diseases involving adenosine signaling would be used. N6-Benzyladenosine would be administered via appropriate routes at doses determined from pharmacokinetic studies. Physiological and behavioral endpoints would be assessed depending on the model. However, specific in vivo protocols for N6-Benzyladenosine have not been detailed in the available literature.
|
| ADME/Pharmacokinetics |
N6-Benzyladenosine has a molecular weight of 357.37 and is soluble in DMSO and other organic solvents. Storage is recommended at 2-8°C or -20°C for long-term stability. The compound is for research use only and is not intended for human or veterinary use. Standard laboratory safety precautions should be followed when handling this compound.
|
| Toxicity/Toxicokinetics |
N6-Benzyladenosine is a research compound intended for laboratory use only and is not for human or veterinary use. As an adenosine receptor agonist, it may affect cardiovascular and neurological function and should be handled with appropriate safety precautions. Comprehensive toxicology studies would be required before any clinical development.
|
| References |
|
| Additional Infomation |
N6-Benzyladenosine (N-Benzyladenosine) is an adenosine receptor agonist with cytokinin activity. It is a selective A1 adenosine receptor agonist that induces G0/G1 cell cycle arrest and apoptosis. N6-Benzyladenosine is a research tool for studying adenosine receptor signaling and is not approved for clinical use.
|
| Molecular Formula |
C17H19N5O4
|
|---|---|
| Molecular Weight |
357.36386
|
| Exact Mass |
357.143
|
| CAS # |
4294-16-0
|
| PubChem CID |
92208
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
689.3±65.0 °C at 760 mmHg
|
| Melting Point |
184-186 °C
|
| Flash Point |
370.7±34.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.763
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
466
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CC=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
|
| InChi Key |
MRPKNNSABYPGBF-LSCFUAHRSA-N
|
| InChi Code |
InChI=1S/C17H19N5O4/c23-7-11-13(24)14(25)17(26-11)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23-25H,6-7H2,(H,18,19,20)/t11-,13-,14-,17-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-[6-(benzylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~349.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7983 mL | 13.9915 mL | 27.9830 mL | |
| 5 mM | 0.5597 mL | 2.7983 mL | 5.5966 mL | |
| 10 mM | 0.2798 mL | 1.3991 mL | 2.7983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
